Qualified Health Claim

A qualified health claim is a health claim — meaning it characterises the relationship between a substance and a disease or health-related condition — that the FDA permits to be made on a product label despite the supporting science not meeting the 'Significant Scientific Agreement' (SSA) threshold required for an authorised health claim under §403(r)(1)(B). The QHC must be accompanied by FDA-prescribed qualifying language that communicates the limitation of the evidence. The qualifying language is non-negotiable; brands cannot paraphrase or summarise.

Obtaining a new QHC is petition-based:

• Petition assembly — petitioner compiles all relevant human-intervention and observational studies, animal models (with caveats), in vitro studies, and meta-analyses. Submits to FDA Office of Nutrition and Food Labeling.
• FDA evidence review — FDA evaluates per the 2009 Evidence-Based Review System. Strength-of-evidence rating (A / B / C / D); QHCs at C or D level require correspondingly stronger qualifying language. A-level evidence may upgrade to authorised claim.
• Public comment — FDA opens docket; interested parties submit comments. Typical review timeline 18–36 months from petition.
• Letter of Enforcement Discretion (LOED) — if FDA approves the QHC, it issues a letter specifying: (a) the substance, (b) the disease / condition, (c) the eligibility criteria (e.g. minimum dose per serving), (d) the EXACT qualifying language that must accompany the claim, (e) any disqualifying conditions.
• Publication — FDA publishes the LOED on the public QHC database. Any qualified party may use the claim provided they meet the eligibility criteria and use the exact prescribed language.
• Denial — if FDA denies the petition, the brand may not use the claim. The denial typically explains the evidence gap; further petition with new evidence is permitted.

• Omega-3 fatty acids EPA/DHA and reduced risk of coronary heart disease — FDA letter 8 Sep 2004, with prescribed wording specifying evidence is supportive but not conclusive.
• Selenium and reduced risk of certain cancers — FDA letter 28 Feb 2003, with prescribed wording cautioning that some scientific evidence suggests, but FDA has determined the evidence is limited and not conclusive.
• Tomatoes / lycopene and reduced risk of prostate, ovarian, gastric, and pancreatic cancers — FDA letter 8 Nov 2005, with prescribed wording specifying very limited and preliminary scientific research.
• Walnuts and reduced risk of coronary heart disease — FDA letter 9 Mar 2004, with prescribed wording specifying supportive but not conclusive research.
• Calcium and reduced risk of hypertension — FDA letter 4 Oct 2005, with prescribed wording specifying inconsistent and inconclusive evidence.

QHC is most useful when:

• The brand wants to make a specific disease-or-condition relationship claim that S/F claims cannot legally cover (S/F is limited to structure / function of the body, not disease).
• The supporting evidence is credible but does not meet SSA. The brand is willing to accept the qualifying-language burden in exchange for FDA-blessed claim authority.
• Competitor pressure has established the QHC as marketing norm in the category (e.g. omega-3 / heart QHC).
• Brand wants regulatory certainty — QHC immunises against §403(r)(1)(B) misbranding action as long as eligibility criteria and qualifying language are followed.

S/F claim is preferable when:

• The claim relates to structure or function of the body, not disease (e.g. 'supports immune function', 'maintains healthy joints').
• Brand wants speed — 30-day notification vs 18-36-month petition cycle.
• Brand can substantiate without a petition process and is comfortable with the §101.93 disclaimer.

• Paraphrasing the qualifier — brand summarises 'supportive but not conclusive' as 'shown to support' or 'helps to'. Removes the FDA-prescribed precision; converts to unauthorised health claim.
• Relocating the qualifier — qualifier placed in a footer or disclaimer block far from the claim itself. FDA expects clear and prominent proximity.
• Using claim without meeting eligibility criteria — QHC eligibility typically requires minimum per-serving dose or specific qualifying substance form. Marketing claim despite not meeting criteria is misbranding.
• Combining QHC with implied claim that exceeds the LOED — e.g. using approved omega-3/CHD QHC alongside marketing imagery that implies cure or prevention of heart attack. The implied claim exceeds the approved scope.
• Crossing into drug claim — disease-treatment or -prevention claim (cure, treat, mitigate) is drug-claim territory, not QHC. Even an approved QHC cannot be paraphrased into curative language.
• Stale LOED — FDA may revise or withdraw a QHC if new evidence emerges. Using a withdrawn QHC is misbranding. Brands should subscribe to FDA QHC database updates.
• Foreign-market QHC variants — EU has its own EFSA-evaluated health-claim regime; US QHC wording is not portable to EU label.

• QHC register: per-claim entry with LOED reference number + date, prescribed qualifying language (exact wording), eligibility criteria (substance form, per-serving minimum, disqualifying conditions), withdrawal / revision status.
• Eligibility-check at SKU configuration: SKU configured to use a QHC must meet eligibility criteria (per-serving dose, substance form) verified against finished-product spec; non-eligible SKU blocked from using the claim.
• Claim-text lock: QHC text on label is system-controlled, not free-text; locked to FDA-prescribed wording; cannot be edited without re-approval from regulatory affairs + change-control.
• Proximity enforcement: label-design template requires QHC qualifier within prescribed proximity (typically same paragraph or immediately adjacent block) of the claim; reviewer cannot approve label that separates them.
• Imagery audit: marketing imagery review checklist flags imagery that may imply claim exceeding LOED scope (e.g. heart imagery alongside omega-3 claim; reviewer confirms imagery does not imply curative effect).
• FDA database sync: scheduled (monthly) sync against FDA QHC database; surfaces any new LOED, revision, or withdrawal; triggers re-review of any SKU using affected claim.
• Claim usage register: per-SKU log of which QHCs are used + which LOED version was current at SKU release; supports inspection-response and adverse-event response.
• S/F vs QHC decision support: at claim-design stage, V5 surfaces side-by-side comparison (substantiation burden, time-to-launch, qualifying-language requirement) to help regulatory team choose appropriate claim type.